Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005520 · ClinicalTrials.gov registry record
Genetic Epidemiology of Responses to Antihypertensives
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 1,200
- Enrollment target
NCT00005520: Completed study, sponsored by Mayo Clinic.
NCT00005520 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 1,200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005520 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 1,200 participants
- Enrollment target
Study Summary
To determine whether measured variation in genes coding for components of vasoconstriction and volume regulating systems predict interindividual differences in blood pressure response to therapy with a thiazide diuretic, hydrochlorothiazide, or an angiotensin II receptor blocker, candesartan, in hypertensive African-Americans (N=300 treated with each drug) and in hypertensive European Americans (N=300 treated with each drug).
Primary Outcome
The blood pressure response to antihypertensive drug therapy was defined by the difference between blood pressure levels prior to and at the end of drug therapy.
Interventions
- DRUG Candesartan
- DRUG Hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 1997-02 |
| Est. Completion | 2008-01 |
What the finished NCT00005520 record still lists
NCT00005520 is an observational study that tracks outcomes without assigning an intervention. Its 1,200 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Candesartan is the first listed.
NCT00005520 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005520 about?
NCT00005520 is a clinical study titled "Genetic Epidemiology of Responses to Antihypertensives". To determine whether measured variation in genes coding for components of vasoconstriction and volume regulating systems predict interindividual differences in blood pressure response to therapy with a thiazide diuretic, hydrochlorothiazide, or an angiotensin II receptor blocker, candesartan, in hyp...
What is the current status of trial NCT00005520?
This trial is currently completed. The enrollment target is 1,200 participants. The study started on 1997-02. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00005520?
The interventions under investigation include: Candesartan (DRUG), Hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT00005520?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001987 · 1,200 participants
Genetic Studies of Insulin and Diabetes
- NCT00477100 · 1,200 participants
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- NCT01209000 · 1,200 participants
Nephrotic Syndrome Study Network
- NCT01944332 · 1,200 participants · NA
Gamete Treatment to Correct Fertilization Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia